4 results
The primary objective is to compare the overall survival (OS) of patients receiving ASA404 or placebo in combination with paclitaxel and carboplatin for first-line treatment of stage IIIb/IV NSCLC
The aim of this study is to investigate how quickly and to what extent aticaprant is absorbed, transported, and eliminated from the body (this is called pharmacokinetics). For this study, aticaprant is radioactively labelled with carbon-14 (14C). In…
To evaluate the relative oral bioavailability and dose proportionality of concept formulations compared with the reference formulation of aticaprant when administered in healthy adult participants. This part will be conducted by PRA.To evaluate the…
We will assess the safety of adalimumab-800CW through the evaluation of both vital signs after tracer administration and possible (severe) adverse events (SAE/AE*s). Importantly, we will determine the feasibility of molecular fluorescence imaging…